2026.03.30 / News

3SBio Announces 2025 Annual Results: Dual Engines of Innovative R&D and Global Collaboration Propel Revenue Past RMB 10 Billion Milestone

2025.08.29 / News

3SBio Announces 2025 Interim Results: Value Realization of Innovative Achievements and Strong Long-Term Growth Momentum

2025.03.25 / News

3SBio Unveils 2024 Annual Results: Profit Surges 34.9% YoY, Innovation Pipeline Delivers Strong Value

2024.08.22 / News

3SBio Unveils 2024 Interim Results: Revenue Up 16% YoY, Autoimmune Pipeline Poised for a Promising Phase

2024.03.20 / News

3SBio reveals 2023 annual results: Revenue surges by 13.8% year on year, with pipelines to reap the rewards

3SBio will remain steadfast in its role as a national biopharmaceutical leader

2023.03.21 / News

3SBio announces 2022 annual results, with revenue rising 7.5% year on year and normalized net profit attributable to parents jumping 25.2%

3SBio is committed to sharpening its focus on refined management and ensuring the healthy developmen...